1Hasinoff, B.B., Oxyradical production results from the Fea(+)-doxorubicin complex undergoing self-reduction by its alpha-ketol group. Biochem Cell Biol, 1990.68( 12): 1331-6.
2Doroshow,J.H.,GY Locker and C.E.Myers,Enzymatic defenses of the mouse Heart against reactive oxygen metabolites:alterations Produced by doxorubicin.J Clinlnvest,1980.65(1):128-35.
3Abdel-aleem, S.,et al., Acute and chronic effects of adriamycin on fatty acid oxidation in isolated cardiac myocytes. J Mol Cell Cardiol, 1997. 29(2): 789-97.
4Kim, S.Y, et al.,Doxorubicin-induced reactive oxygen species generation and intracellular Ca2+ increase are reciprocally modulated in rat cardiomyocytes. Exp Mol Med,2006.38(5):p.535-45.
5De Beer, E.L.,A.E. Bottone,and E.E. Voest, Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment:areview.Eur J Pharmacol,2001.415( 1): 1-11.
6Bemardi,E,et al.,Mitochondria and cell death. Mechanistic aspects and methodological issues. Eur J Biochem,1999. 264(3):p.687-701.
7Fulda,S.,et al.Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis.Oncogene, 2001, 20(9):1063-75.
3Pongprot Y, Sittiwangkul R, Charoenkwan P, et al. Use of cardiac markers for monitoring of doxorubixin-induced cardiotoxicity in children with cancer[ J ]. J Pediatr Hematol 0ncol,2012,34 (8) : 589-595.
4Miller CL, Cai Y, Oikawa M, et al. Cyclic nucleotide phosphodiesterase 1A:a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart [ J ]. Basic Res Cardio1,2011,106 (6) : 1023-1039.
5Shibayama J, Yuzyuk TN, Cox J, et al. Metabolic remodeling in moderate synchronous versus dyssynchronous pacing-induced heart failure: integrated metabolomics and proteomics study [ J ]. PLoS One, 2015,10(3) :e0118974.
6Doenst T, Pytel G, Schrepper A, et al. Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload [ J ]. Cardiovasc Res,2010, 86(3) :461-470.
